Weiming You

Xi'an, 710004, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 30 publications

A supramolecular peptide reprograms PD-L1+ tumor-associated macrophages to enhance antitumor immunity in lung adenocarcinoma.

A supramolecular peptide reprograms PD-L1+ tumor-associated macrophages to enhance antitumor immunity in lung adenocarcinoma.

Journal: Journal of controlled release : official journal of the Controlled Release Society

Published: November 09, 2025

Selenium nanoparticle-delivered MDM2 inhibitor reactivates p53 and reprograms tumor immune microenvironment in colorectal cancer.

Selenium nanoparticle-delivered MDM2 inhibitor reactivates p53 and reprograms tumor immune microenvironment in colorectal cancer.

Journal: Frontiers in immunology

Published: August 12, 2025

A bifunctional peptide-selenium nanocomposite for lysosomal degradation of PD-L1 and enhanced cancer immunotherapy.

A bifunctional peptide-selenium nanocomposite for lysosomal degradation of PD-L1 and enhanced cancer immunotherapy.

Journal: Frontiers in immunology

Published: August 03, 2025

Disrupting β-Catenin/BCL9 interaction with a peptide prodrug boosts immunotherapy in colorectal cancer.

Disrupting β-Catenin/BCL9 interaction with a peptide prodrug boosts immunotherapy in colorectal cancer.

Journal: Frontiers in immunology

Published: July 09, 2025

Dual-targeted N-PMIplus@CA nanoplatform for concurrent MDM2 and β-catenin inhibition in p53 wild-type lung adenocarcinoma.

Dual-targeted N-PMIplus@CA nanoplatform for concurrent MDM2 and β-catenin inhibition in p53 wild-type lung adenocarcinoma.

Journal: Materials today. Bio

Published: June 07, 2025

Artificial Intelligence-Guided Cancer Engineering for Tumor Normalization Executed by Tumor Lysosomal-Triggered Supramolecular Chiral Peptide.

Artificial Intelligence-Guided Cancer Engineering for Tumor Normalization Executed by Tumor Lysosomal-Triggered Supramolecular Chiral Peptide.

Journal: ACS nano

Published: April 29, 2025

Bionic Power Play: Dual-Targeting MDMX/MDM2 to Reboot p53 to Beat Lung Adenocarcinoma's Immune Tricks.

Bionic Power Play: Dual-Targeting MDMX/MDM2 to Reboot p53 to Beat Lung Adenocarcinoma's Immune Tricks.

Journal: International journal of nanomedicine

Published: April 08, 2025

Bringing p53 Back: A Prion-Powered Attack on Retinoblastoma.

Bringing p53 Back: A Prion-Powered Attack on Retinoblastoma.

Journal: International journal of biological sciences

Published: March 03, 2025

Retraction Note: Carnosic acid nanocluster-based framework combined with PD-1 inhibitors impeded tumorigenesis and enhanced immunotherapy in hepatocellular carcinoma.

Retraction Note: Carnosic acid nanocluster-based framework combined with PD-1 inhibitors impeded tumorigenesis and enhanced immunotherapy in hepatocellular carcinoma.

Journal: Functional & integrative genomics

Published: February 28, 2025

From foe to friend: Rewiring oncogenic pathways through artificial selenoprotein to combat immune-resistant tumor.

From foe to friend: Rewiring oncogenic pathways through artificial selenoprotein to combat immune-resistant tumor.

Journal: Journal of pharmaceutical analysis

Published: January 18, 2025

Resurrecting p53 by an Artificial Nano-Protein for Potent Photodynamic Retinoblastoma Therapy.

Resurrecting p53 by an Artificial Nano-Protein for Potent Photodynamic Retinoblastoma Therapy.

Journal: Small (Weinheim an der Bergstrasse, Germany)

Published: February 17, 2024

A Transdermal Prion-Bionics Supermolecule as a RAB3A Antagonist for Enhancing Facial Youthfulness.

A Transdermal Prion-Bionics Supermolecule as a RAB3A Antagonist for Enhancing Facial Youthfulness.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Published: November 15, 2023

Showing 1-12 of 30

Last Updated: 09/26/2026